Phase II study of Gleevec® plus hydroxyurea in adults with progressive or recurrent low-grade glioma()

BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratified patients into astrocytoma and oligodendrog...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Herndon, James E., Coan, April, Gururangan, Sridharan, Peters, Katherine B., McLendon, Roger, Sathornsumetee, Sith, Rich, Jeremy N., Lipp, Eric S., Janney, Dorothea, Friedman, Henry S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3748946/
https://ncbi.nlm.nih.gov/pubmed/22371319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26541
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares